• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Seqirus

Pharma

CSL Seqirus to trial avian vaccine candidate in $30M BARDA deal

The company scored $30.1 million from BARDA to make and trial the vaccine candidate.
Zoey Becker Oct 10, 2022 10:39am

CSL to unite all business units under one umbrella

Aug 26, 2022 8:12am

Flu vaccine makers gear up for a busy season ahead

Aug 17, 2022 3:05pm

GSK has a busy flu shot season ahead in Canada and the US

Jul 18, 2022 9:03am

Sanofi isn't the only one clamoring for better flu shot guidance

Jun 23, 2022 8:00am

Seqirus completes $156M expansion at fill-finish plant

Jun 9, 2022 9:35am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy